1 / 8

SAFETY OF INFLUENZA VACCINATION

SAFETY OF INFLUENZA VACCINATION. Symptom. Vaccine (%). Placebo (%). Feverish. 5.7. 4.2. Malaise. 7.2. 6.3. Myalgia. 4.8. 4.2. Headache. 6.9. 7.6. Nausea. 4.5. 2.4. Sore arm. 20.1. 4.9. Influenza vaccine post - injection symptoms in elderly subjects.

malcolm-reynolds
Download Presentation

SAFETY OF INFLUENZA VACCINATION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SAFETY OF INFLUENZA VACCINATION

  2. Symptom Vaccine (%) Placebo (%) Feverish 5.7 4.2 Malaise 7.2 6.3 Myalgia 4.8 4.2 Headache 6.9 7.6 Nausea 4.5 2.4 Sore arm 20.1 4.9 Influenza vaccine post-injection symptoms in elderly subjects Soreness at the site of injection isthe only common side effect Margolis KL et al. JAMA 1990; 264: 1139–41.

  3. Safety issues with influenza vaccines • Influenza vaccines have an excellent safety profile • Influenza vaccination is contraindicated if the patient has: • An allergy to any constituent • An acute febrile illness • Previous Guillain-Barré syndrome (GBS) within6 weeks of vaccination • Concerns have been raised about: • The sporadic association of GBS with influenza vaccination (rare: < 1 per million vaccine doses) • Exacerbations of asthma (may occur, but are uncommonand rarely severe) • Generally, the benefits of vaccination outweigh the risks

  4. GBS and influenza vaccination • An unexplained increase in the risk of GBS occurred among recipients of the swine influenza vaccine in the USA in 1976–77 • From July 1990–June 2003, the US Vaccine Adverse Events Reporting System (VAERS) received 501 reports of GBS following influenza vaccination in adults • The median onset interval (13 days) was longer than thatof non-GBS reports of adverse events after influenza vaccine(1 day) • The annual reporting rate decreased 4-fold from a highof0.17 per 100,000 vaccinees in 1993–1994 to 0.04 in 2002–2003 • A GBS diagnosis was confirmed in 82% of reports • Preceding illness within 4 weeks of vaccination was identified in 24% of reported cases Haber P et al. JAMA 2004; 292: 2478–81.

  5. Influenza vaccination and exacerbations of asthma • The pooled results of two trials involving 2306 individuals with asthma did not demonstrate a significant increase in asthma exacerbations in the 2 weeks following influenza vaccination • A recent study of 696 children with asthma did not demonstrate a significant reduction in influenza-related asthma exacerbations Cates CJ et al. Cochrane Database Syst Rev 2004; 2: CD000364.

  6. After influenza vaccination What we need to advise patients: • Take paracetamol as advised (paracetamol priorto influenza vaccination can berecommendedfor children) • Drink extra fluids • Place a cool flannel at the site of the injection • Advise them to contact you if they haveanyunexpected reaction to influenza vaccination orif they are at all concerned • Most people generally tolerate influenza vaccine well . National Influenza Immunisation Strategy Group.

  7. A summary – vaccinationin practice

  8. By courtesy of APACIAsia-Pacific Advisory Committee on influenzawww.apaci-flu.com

More Related